C. Maurin

A Phase I/II open-label trial of intravenous allogeneic mesenchymal stromal cell therapy in adults with recessive dystrophic epidermolysis bullosa.

J. R. McMillan, J. McGrath, C. Ainali, 2019, Journal of the American Academy of Dermatology.

Safety and early efficacy outcomes for lentiviral fibroblast gene therapy in recessive dystrophic epidermolysis bullosa.

F. Reid, J. Tolar, M. del Río, 2019, JCI insight.